Fig. 6
Reduced C/EBPβ expression in LysMCre-C/EBPβfl/fl microglia in vivo. a Representative Western blot showing C/EBPβ protein levels in microglia acutely isolated in vivo from the brains of C/EBPβfl/fl and LysMCre-C/EBPβfl/fl mice treated i.p. with vehicle (C) or LPS (4 mg/kg) for 16 h. Two C/EBPβ isoforms are detected, Full (~38 kDa) and LAP (~35 kDa). b Quantification of Western blot signals from experiments as that shown in a (n = 4 mice/condition. C/EBPβ protein levels are normalized using β-actin levels. Data are shown as mean + SEM. LPS induces a significant increase in C/EBPβ protein levels in C/EBPβfl/fl microglia (***p < 0.001, compared with respective vehicle) and not in LysMCre-C/EBPβfl/fl microglia (###p < .001, compared with C/EBPβfl/fl). c Immunocytochemistry for C/EBPβ (red) and the microglial marker CD68 (green) in cytospin preparations of microglia isolated from the brains of C/EBPβfl/fl and LysMCre-C/EBPβfl/fl mice treated as in a. Note the absence of C/EBPβ immunoreactivity in microglia from vehicle-treated mice, the nuclear C/EBPβ staining in virtually all microglial cells from LPS-treated C/EBPβfl/fl mice and the presence of C/EBPβ in a small fraction of microglial cells from LPS-treated LysMCre-C/EBPβfl/fl mice. Scale bar 25 μm. d Quantification of the proportion of C/EBPβ immunoreactive microglial cells in cytospin preparations as that shown in c. Data are expressed as percentage of C/EBPβ immunoreactive microglial cells and are shown as mean + SEM (n = 3 mice/condition). ***p < 0.001, compared with respective vehicle; ###p < .001, compared with respective C/EBPβfl/fl